see also:

• hepatitis
• liver diseases

• steatohepatitis is a progression of fatty liver disease and may progress on to cirrhosis and hepatocellular carcinoma
• initially it is asymptomatic and may only be discovered as a result of:
  • raised liver function tests (LFTs)
  • hepatomegaly
  • diagnosis on USS or CT abdo
• it is classified into:
  • alcoholic steatohepatitis
  • non-alcoholic steatohepatitis (NASH)
  • acute fatty liver of pregnancy (AFLP)

• this is due to excessive alcohol intake
  • 6 standard glasses (80g alcohol) over 1-3 days will cause a mild reversible hepatic steatosis with microvesicular lipid droplets accumulating in hepatocytes
  • chronic ingestion, esp. more than 80g/d, leads to macrovesicular lipid globules within hepatocytes which compress and displace the nucleus to the periphery and is also associated with increase in inflammatory cells, esp. neutrophils, in the liver, and may result in increase of liver size to 4-6kg
    • this may then cause fibrosis around terminal hepatic veins which extends into adjacent sinusoids and risk development of cirrhosis

• currently affects 3.5-5% of adults in Western cultures and > 75% of those with morbid obesity
• risk factors:
  • high fructose diet
    • excessive fructose metabolism in intestinal cells reduces production of proteins that maintain the gut barrier and can cause a chronic endotoxaemia which in the liver is thought to provoke increased production of inflammatory cytokines and stimulate the conversion of fructose and glucose into fatty acid deposits¹⁾
  • metabolic syndrome
  • central obesity
  • hyperglycemia
  • type 2 diabetes
  • arterial hypertension
  • hypertriglyceridemia
  • chronic PM_2.5 particle exposure ²⁾
  • genetic factors³⁾:
    • PNPLA3 (I148M, rs738409): the strongest risk allele linked to lipid droplet metabolism dysfunction in hepatocytes and stellate cells, promoting steatosis, fibrosis, and HCC;
    • TM6SF2 (E167K, rs58542926): impairs very-low-density lipoprotein (VLDL) secretion, leading to triglyceride retention;
    • MBOAT7 (rs641738): alters phospholipid remodelling and predisposes to hepatic lipid accumulation;
    • HSD17B13 (rs72613567): confers a protective effect, reducing steatosis and inflammation.
• it is a progression from nonalcoholic fatty liver disease (NAFLD) which affects ~20% of the population in Western cultures and is rising rapidly due to obesity
  • 90% of obese patients have NAFLD, while up to 70% of type 2 diabetics have NAFLD
• two sub groups:
  • metabolic dysfunction-associated steatotic liver disease (MASLD)
  • metabolic dysfunction-associated steatohepatitis (MASH)
    • appears to substantially improve with glucagon-like peptide-1 (GLP-1) peptide analogs (eg. Ozempic)
    • substantially increases risk of hepatocellular carcinoma by triggering p53-dependent actions on the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) initially resulting in hepatocyte senescence⁴⁾
• histologically, it is characterised by unique zone 3 “chicken wire” fibrosis
• accounts for 13% of all cases of hepatocellular carcinoma
• in the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial, for patients with NASH but without diabetes mellitus, the use of very high dosages of vitamin E (800 IU/day) for four years was associated with a significantly higher rate of improvement than placebo (43% vs. 19%) in the primary outcome
• premenopausal women are relatively protected from it due to high oestrogen levels, but risk increases in peri-menopausal women and post-menopausal women
  • modulation of oestrogen receptor alpha (ER-α) activity increases the risk of steatohepatitis in vulnerable women - reduced E2 levels in postmenopausal women often lead to insulin resistance (IR) and changes in adiposity, which also trigger the phenotypic expression of the PNPLA3 p.I148M variant. ⁵⁾
  • the p.I148M variant of PNPLA3 accounts for the highest proportion of NAFLD heritability and accounts for 27% and 16% of HCC and cirrhosis variance, respectively.⁶⁾
• role of impaired urea cycle in fatty liver disease
  • Arginases mediate arginine hydrolysis to ornithine and urea. ARG1 is the more highly expressed arginase isoform in hepatocytes, whereas Arg2 is minimally expressed in liver under basal, fed conditions but ARG2 deficiency appears to be a driving factor of fatty liver disease.
  • Obesity impairs hepatocyte ureagenic and oxidative gene expression. Hepatocyte Arg2 deletion impairs ureagenesis, TCA cycle, and mitochondrial function. Hepatocyte Arg2 deficiency drives obesity, liver steatosis, and insulin resistance with aging. The urea cycle defects lead to secondary impairment in the tricarboxylic acid (TCA) cycle, a key pathway for energy metabolism. This disruption results in inefficient calorie utilization and excessive fat storage in the liver, which can subsequently cause inflammation and fibrosis, contributing to the progression of the disease. ⁷⁾
• role of miR-93 in MASLD
  • “miR-93 was significantly upregulated in the livers of patients with MASLD and diet-induced obese mice. miR-93 KO mice exhibited reduced hepatic steatosis. Specifically, miR-93 deficiency upregulated genes involved in fatty acid oxidation and downregulated genes associated with cholesterol biosynthesis. Sirtuin 1 (SIRT1) was identified as a direct target of miR-93, and miR-93 KO enhanced SIRT1 expression and activated the LKB1-AMPK signaling pathway. Niacin treatment downregulated miR-93, ameliorating hepatic steatosis by enhancing SIRT1 activity” ⁸⁾

• a rare condition mainly of the 3rd trimester (1 in 13,000 deliveries)
• may cause hepatic failure, coma and death
• may have concurrent pre-eclampsia and eclampsia